BioMS Medical initiates enrollment in pivotal US phase III ...
Canada NewsWire (press release) - Canada
MINDSET-01 is a phase II trial evaluating MBP8298 for the treatment of relapsing-remitting multiple sclerosis (RRMS). The trial is a randomized, ...
See all stories on this topic

Pleasantville business among winners of 'million-dollar business ...
White Plains Journal News - White Plains,NY,USA
Acorda intends to use proceeds from the offering to complete a second Phase 3 trial of Fampridine-SR, a treatment for multiple sclerosis, and other business ...
See all stories on this topic

FDA to Review Biogen's Crohn's Disease Treatment
FDA news (subscription) - Falls Church,VA,USA
A joint FDA Drug Safety and Risk Management/Gastrointestinal Drugs Advisory Committee will review Biogen Idec/Elan's multiple sclerosis (MS) agent Tysabri ...
See all stories on this topic